(CCEL) CryoCell International - Ratings and Ratios

Cryo-Cell International Inc (NYSE MKT:CCEL) is a company that specializes in the collection, processing, and cryogenic storage of umbilical cord blood stem cells, primarily for family use. The company also offers cord tissue storage services, which involve preserving a section of the umbilical cord tissue containing mesenchymal stem cells. These stem cells have the potential to be used in regenerative medicine to treat various medical conditions. Additionally, Cryo-Cell manufactures and markets the PrepaCyte CB processing system, a technology designed to process umbilical cord blood stem cells.

The companys business model involves direct marketing to expectant parents, as well as partnerships with healthcare professionals such as obstetricians, pediatricians, and childbirth educators to promote its cord blood stem cell preservation services. With its headquarters in Oldsmar, Florida, Cryo-Cell has been operating since its incorporation in 1989. The companys online presence is available at https://www.cryo-cell.com.

From a technical analysis perspective, CCELs stock price has been trending downward, with its 50-day and 200-day simple moving averages (SMA) at $5.72 and $6.66, respectively, indicating a potential bearish trend. The Average True Range (ATR) of 0.33, equivalent to 6.29%, suggests moderate volatility. Given the current price of $5.24, and considering the SMA20 at $5.17, a potential buy signal may be generated if the stock price continues to rise above the SMA20. However, if the downward trend persists, it may be wise to exercise caution.

Fundamentally, Cryo-Cells market capitalization stands at $40.41M USD, with a high P/E ratio of 500, indicating that the stock may be overvalued. The absence of a forward P/E ratio makes it challenging to gauge future earnings expectations. The companys return on equity (RoE) is negative at -1.07, suggesting that the company is currently unprofitable. Combining technical and fundamental analysis, a forecast for CCELs stock price may involve a potential short-term bounce if it breaks above the SMA20, but the long-term outlook remains uncertain due to the companys current unprofitability and high valuation.

To make an informed investment decision, its essential to weigh the potential benefits of Cryo-Cells innovative services and products against the risks associated with its current financial performance and market trends. A thorough analysis of the companys future earnings potential, competitive landscape, and industry growth prospects is necessary to determine the stocks potential for long-term growth.